Last week, we gathered at The Explorer's Club in NYC for the first AI Leadership Salon to have a necessary conversation – how are we using AI in ways that support a better future – and what’s next as AI systems move beyond our ability to truly manage them? #AI #TechBio @recursionpharma.bsky.social

Had an incredible time at @recursionpharma.bsky.social's #TechBio Symposium in SLC last week learning about our latest tech breakthroughs and partnership programs & the Recursion approach to drug discovery. Especially loved connecting with my colleagues from across the country & across the pond!

🎉 Excited to see that the just-announced $46 billion UK-US Tech Prosperity Deal is putting significant emphasis on AI drug discovery, including: 🧵

It's not easy for a reporter to capture the way a company works from the inside - the people driving it, their motivations. It requires access, transparency, & really sharp storytelling skills. All of those came together in this @wired.com feature from Veronique Greenwood. wired.com/story/artifi...

“I’m still the hope guy.” Two nights ago I had the great privilege of taking my daughters to see @barackobama.bsky.social in conversation with historian Heather Cox Richardson at the Bushnell in Hartford. He offered a perspective that only he can on the moment we are in. 🧵

Researchers at MIT and @recursionpharma.bsky.social just released the first AI tool to solve protein binding affinity prediction at scale – a major hurdle in drug discovery – and it's completely open source. www.youtube.com/watch?v=gRtr... #TechBio #openscience 🧪

🚀 5 open science initiatives that are driving new discoveries. A number of big pharma, academic research groups & #TechBio companies are providing open source tools, data, and software to drive new discoveries that can lead to new cures. 💥 Here are 5 efforts making an impact. 🧪🧵

Public datasets fall short when it comes to reliably training AI models for drug discovery. In a new blog, I share how @recursionpharma.bsky.social is helping to fill the gap by providing open source versions of its massive, proprietary cellular screening datasets. www.recursion.com/news/acceler...

🏆 Science deserves to be celebrated. A recent story by Ian Sample in @theguardian.com details the fascinating life of David R. Liu, a professor at the @broadinstitute.org of MIT & Harvard and one of the winners of the $3m Breakthrough Prize for Life Sciences, known as the “Oscars of Science.” 🧪🧵

I dove pretty deep into the autism-environmental toxin connection. There's compelling science behind it -- even more so now then when I wrote The Autism Puzzle -- and I'm glad to see it getting more public attention. #autism #ASD www.sevenstories.com/books/3571-t... 🧪

New story from Erika Fry in @fortune.com on @recursionpharma.bsky.social's long climb to leading #AI drug discovery company. She looks at skepticism head on & details 3 ingredients needed to succeed: massive data, massive computing power & a serious appetite for risk. fortune.com/2025/04/03/r... 🧪

🧪 I love stories of accidental scientific discovery. (Penicillin! The smallpox vaccine! Insulin!) So I was particularly excited to discover that one of the great scientific breakthroughs of our time – CRISPR-Cas9 gene editing – was the result of a similar kind of fortuitous accident. 🧵

Today at #NeurIPS I was introduced to game theory for literature, applying LLMs to Romeo & Juliet to crack the code on characters & assess how various decisions they might make will be received, i.e. “future payoff.” To bring mathematical structure to stories & maybe guide real-life decision making.

On Mon., Dec. 9 at the @theaacr.bsky.social Special Conference in Cancer Research, CSO David Hallett will present the 1st monotherapy data readouts from the ELUCIDATE PH1/2 trial for REC-617, a potential best-in-class CDK7 inhibitor. On Tues., Dec. 10, 8:30-9am ET we're holding a live update call. 🧵

👀 What will be the biggest stories in #ML to emerge at @neuripsconf.bsky.social in Vancouver next week? In AI drug discovery: foundation models & agentic systems. I'll be w/ @valenceai.bsky.social & @recursionpharma.bsky.social - w/ over 12+ accepted papers - who can discuss our breakthroughs!

Heads up that I made a #TechBio feed on @bsky.app -- just use the #TechBio hashtag to be included! bsky.app/profile/did:...

How a study on whether rats could drive turned into a study on whether rats experience joy in driving. Spoiler alert: they do. www.independent.co.uk/news/science...

The Hack Week project that changed the way @recursionpharma.bsky.social images cells — from CellPaint to, now, brightfield microscopy. A fascinating deep dive from @owlposter.bsky.social #techbio

Is there an East Coast-West Coast #biotech culture divide? Interesting perspective from @dshaywitz.bsky.social on how Boston leans more biotech & SF leans more AI, building on insights from Chandana Haque, Dir of Altitude Labs @recursionpharma.bsky.social #techbio timmermanreport.com/2024/11/coas...

The call is coming. Nov. 20, 7:30am ET, tune in live to hear what’s next for AI drug discovery after @recursionpharma.bsky.social & Exscientia officially combine to form one leading TechBio powerhouse. Join the livestream on YouTube here: m.youtube.com/channel/UCXZ... #techbio

Love coming back to Utah. Bring on the snow!

In a new blog, I share the story of MolE — a foundation model for #chemistry just published in Nature. MolE was trained on ~842 million molecules in a self-supervised manner & fine-tuned on downstream ADMET tasks, ranking 1st in 10 of 22 tasks. communities.springernature.com/posts/introd...